THERAPIES FOR CHRONIC MYELOID LEUKAEMIA
Professor Tim Hughes
Clinical Director Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI)
& Consultant Haematologist, Royal Adelaide Hospital, South Australia
RESEARCHER PROFILE (Filmed in Adelaide, South Australia | December 2024)
Professor Tim Hughes is the Chronic Myeloid Leukaemia Group Leader at SAHMRI, Clinical Director in the Precision Cancer Medicine Theme at SAHMRI and Consultant Haematologist in the Division of Haematology at SA Pathology and at the Royal Adelaide Hospital.
He is also Inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS) and Fellow of the Australian Academy of Science.
Professor Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times.
He has been recognised for his achievements with several national awards including the GSK Award for Research Excellence in 2017 for pioneering the use of tyrosine kinase inhibitors (TKIs) and the Ramaciotti Medal for Excellence in Biomedical Research in 2019. He was also awarded the International CML Foundation Goldman Prize in 2017 for lifetime contributions to improving outcomes for patients with CML.
-
Biomarkers for early sepsis detection
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
-
Radiation therapy techniques and combination treatments for sarcoma
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
